FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016826612> ?p ?o ?g. }

• W2016826612 endingPage "420" @default.
• W2016826612 startingPage "411" @default.
• W2016826612 abstract "Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various 'calmodulin antagonists' for these sites was investigated. The Ki values for the inhibition of calmodulin-activated cyclic-nucleotide phosphodiesterase and myosin light-chain kinase was determined. In addition, the Kd values of the same compounds for binding to calmodulin were measured. The compounds could be separated into four groups. Group I and II compounds inhibited competitively the activation of the phosphodiesterase and myosin light-chain kinase by calmodulin. Group I compounds inhibited the activation of the phosphodiesterase and myosin light-chain kinase at identical concentrations. In contrast, group II compounds inhibited the activation of the phosphodiesterase at 5-10-fold lower concentrations than that of myosin light-chain kinase. Group III compounds inhibited the activation of these enzymes by an uncompetitive mechanism. Group IV compounds inhibited the activation of the phosphodiesterase with Ki values above 10 microM and did not affect the activation of myosin light-chain kinase. Binding of [3H]bepridil to calmodulin under equilibrium conditions yielded one high-affinity site (apparent Kd 0.4 microM) and four low affinity sites (apparent Kd 44 microM). Group I compounds interfered with the binding of bepridil to the high and low-affinity sites in a competitive manner. Group II compounds interfered in a non-competitive manner with the high-affinity site and apparently competed only with one of the low-affinity sites. Group III compounds did not compete with any of the bepridil-binding sites. Nimodipine, a group III compound, bound to one site on calmodulin with a Kd value of 1.1 microM. Other dihydropyridines competed with [3H]nimodipine for this site. The group I and II compounds, trifluoperazine and prenylamine, did not affect the binding of [3H]nimodipine. These data show that 'calmodulin antagonists' can be differentiated into at least three distinct groups. Kinetic and binding data suggest that the three groups bind to at least three different sites on calmodulin. Selective occupation of these sites may inhibit specifically the activation of distinct enzymes." @default.
• W2016826612 created "2016-06-24" @default.
• W2016826612 creator A5003978039 @default.
• W2016826612 creator A5091874127 @default.
• W2016826612 date "1987-04-01" @default.
• W2016826612 modified "2023-10-13" @default.
• W2016826612 title "Differentiation of the drug-binding sites of calmodulin" @default.
• W2016826612 cites W1519540750 @default.
• W2016826612 cites W1572735837 @default.
• W2016826612 cites W1587807023 @default.
• W2016826612 cites W1598745912 @default.
• W2016826612 cites W1602050362 @default.
• W2016826612 cites W1603542247 @default.
• W2016826612 cites W1650772472 @default.
• W2016826612 cites W1823382097 @default.
• W2016826612 cites W1965607587 @default.
• W2016826612 cites W1973285570 @default.
• W2016826612 cites W1988698924 @default.
• W2016826612 cites W1998493256 @default.
• W2016826612 cites W2006122354 @default.
• W2016826612 cites W2012353885 @default.
• W2016826612 cites W2022789859 @default.
• W2016826612 cites W2026615082 @default.
• W2016826612 cites W2030476191 @default.
• W2016826612 cites W2030669640 @default.
• W2016826612 cites W2037710668 @default.
• W2016826612 cites W2043813981 @default.
• W2016826612 cites W2044381533 @default.
• W2016826612 cites W2046291488 @default.
• W2016826612 cites W2053114711 @default.
• W2016826612 cites W2060848457 @default.
• W2016826612 cites W2063088582 @default.
• W2016826612 cites W2068333789 @default.
• W2016826612 cites W2071219823 @default.
• W2016826612 cites W2073760798 @default.
• W2016826612 cites W2082899685 @default.
• W2016826612 cites W2083442454 @default.
• W2016826612 cites W2084228956 @default.
• W2016826612 cites W2090461679 @default.
• W2016826612 cites W2097575249 @default.
• W2016826612 cites W2141587571 @default.
• W2016826612 cites W37904182 @default.
• W2016826612 doi "https://doi.org/10.1111/j.1432-1033.1987.tb11073.x" @default.
• W2016826612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3032617" @default.
• W2016826612 hasPublicationYear "1987" @default.
• W2016826612 type Work @default.
• W2016826612 sameAs 2016826612 @default.
• W2016826612 citedByCount "53" @default.
• W2016826612 countsByYear W20168266122013 @default.
• W2016826612 countsByYear W20168266122014 @default.
• W2016826612 countsByYear W20168266122015 @default.
• W2016826612 countsByYear W20168266122017 @default.
• W2016826612 countsByYear W20168266122018 @default.
• W2016826612 countsByYear W20168266122019 @default.
• W2016826612 countsByYear W20168266122022 @default.
• W2016826612 crossrefType "journal-article" @default.
• W2016826612 hasAuthorship W2016826612A5003978039 @default.
• W2016826612 hasAuthorship W2016826612A5091874127 @default.
• W2016826612 hasBestOaLocation W20168266121 @default.
• W2016826612 hasConcept C107824862 @default.
• W2016826612 hasConcept C178790620 @default.
• W2016826612 hasConcept C181199279 @default.
• W2016826612 hasConcept C184235292 @default.
• W2016826612 hasConcept C185592680 @default.
• W2016826612 hasConcept C2777022698 @default.
• W2016826612 hasConcept C2778937662 @default.
• W2016826612 hasConcept C2780215583 @default.
• W2016826612 hasConcept C29688787 @default.
• W2016826612 hasConcept C519063684 @default.
• W2016826612 hasConcept C55493867 @default.
• W2016826612 hasConcept C62826618 @default.
• W2016826612 hasConcept C6997183 @default.
• W2016826612 hasConcept C71240020 @default.
• W2016826612 hasConcept C8035138 @default.
• W2016826612 hasConcept C97029542 @default.
• W2016826612 hasConceptScore W2016826612C107824862 @default.
• W2016826612 hasConceptScore W2016826612C178790620 @default.
• W2016826612 hasConceptScore W2016826612C181199279 @default.
• W2016826612 hasConceptScore W2016826612C184235292 @default.
• W2016826612 hasConceptScore W2016826612C185592680 @default.
• W2016826612 hasConceptScore W2016826612C2777022698 @default.
• W2016826612 hasConceptScore W2016826612C2778937662 @default.
• W2016826612 hasConceptScore W2016826612C2780215583 @default.
• W2016826612 hasConceptScore W2016826612C29688787 @default.
• W2016826612 hasConceptScore W2016826612C519063684 @default.
• W2016826612 hasConceptScore W2016826612C55493867 @default.
• W2016826612 hasConceptScore W2016826612C62826618 @default.
• W2016826612 hasConceptScore W2016826612C6997183 @default.
• W2016826612 hasConceptScore W2016826612C71240020 @default.
• W2016826612 hasConceptScore W2016826612C8035138 @default.
• W2016826612 hasConceptScore W2016826612C97029542 @default.
• W2016826612 hasIssue "2" @default.
• W2016826612 hasLocation W20168266121 @default.
• W2016826612 hasLocation W20168266122 @default.
• W2016826612 hasOpenAccess W2016826612 @default.
• W2016826612 hasPrimaryLocation W20168266121 @default.
• W2016826612 hasRelatedWork W1984549180 @default.
• W2016826612 hasRelatedWork W2004888440 @default.

• next